Suppr超能文献

局部晚期宫颈癌根治性放化疗后阴道症状和激素替代治疗对性结局的影响:EMBRACE-I 研究结果。

Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study.

机构信息

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Department of Radiation Oncology, AZ Turnhout, Turnhout, Belgium; Iridium Cancer Network, Antwerp, Belgium.

出版信息

Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):400-413. doi: 10.1016/j.ijrobp.2021.08.036. Epub 2021 Sep 1.

Abstract

PURPOSE

To evaluate patient-reported sexual outcomes after chemoradiation therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer in the observational, prospective, multicenter EMBRACE-I study.

METHODS AND MATERIALS

Sexual outcomes were assessed prospectively with the European Organization for Research and Treatment of Cancer Qualify of Life Questionnaire (EORTC-QLQ-CX24) at baseline and follow-up. Crude incidence and prevalence rates of sexual activity, vaginal functioning problems (dryness, shortening, tightening, pain during intercourse), and sexual enjoyment were evaluated. Associations between pain during intercourse and vaginal functioning problems or sexual enjoyment were calculated, pooling observations over all follow-ups (Spearman correlation coefficient). In patients who were frequently sexually active (≥50% of follow-ups), the effects of regular hormonal replacement therapy (HRT) on vaginal functioning problems were evaluated (Pearson χ).

RESULTS

The analysis involved 1045 patients with a median follow-up of 50 months. Sexual activity was reported by 22% of patients at baseline and by 40% to 47% of patients during follow-up (prevalence rates). Vaginal functioning problems in follow-up were dryness (18%-21%), shortening (15%-22%), tightening (16%-22%), pain during intercourse (9%-21%), and compromised enjoyment (37%-47%). Pain during intercourse was significantly associated with vaginal tightening (r = 0.544), shortening (r = 0.532), and dryness (r = 0.408) and negatively correlated with sexual enjoyment (r = -0.407). Regular HRT was associated with significantly less vaginal dryness (P = .015), shortening (P = .024), pain during intercourse (P = .003), and borderline higher sexual enjoyment (P = .062).

CONCLUSIONS

Vaginal functioning problems are associated with pain and compromised sexual enjoyment. Further effort is required for the primary prevention of vaginal morbidity with dose optimization and adaptation. Secondary prevention strategies, including HRT for vaginal and sexual health after radiation therapy in locally advanced cervical cancer, should be considered and sexual rehabilitation programs should be developed further.

摘要

目的

在观察性、前瞻性、多中心 EMBRACE-I 研究中,评估局部晚期宫颈癌患者接受放化疗和图像引导自适应近距离放疗后的患者报告的性结局。

方法和材料

使用欧洲癌症研究与治疗组织生活质量问卷(EORTC-QLQ-CX24)在基线和随访时前瞻性评估性结局。评估性行为、阴道功能障碍(干燥、缩短、收紧、性交疼痛)和性享受的粗发生率和患病率。计算性交疼痛与阴道功能障碍或性享受之间的关联,汇总所有随访的观察结果(Spearman 相关系数)。在经常有性行为的患者(≥50%的随访)中,评估定期激素替代疗法(HRT)对阴道功能障碍的影响(Pearson χ²)。

结果

该分析涉及 1045 名中位随访时间为 50 个月的患者。基线时 22%的患者报告有性行为,随访期间 40%至 47%的患者报告有性行为(患病率)。随访中的阴道功能障碍包括干燥(18%-21%)、缩短(15%-22%)、收紧(16%-22%)、性交疼痛(9%-21%)和享受度下降(37%-47%)。性交疼痛与阴道收紧(r = 0.544)、缩短(r = 0.532)和干燥(r = 0.408)显著相关,与性享受呈负相关(r = -0.407)。定期 HRT 与阴道干燥(P =.015)、缩短(P =.024)、性交疼痛(P =.003)显著减少和性享受度略有增加(P =.062)相关。

结论

阴道功能障碍与疼痛和性享受度下降相关。需要进一步努力,通过优化和调整剂量来预防阴道发病率,并采取二级预防策略,包括局部晚期宫颈癌放疗后进行阴道和性健康的 HRT,还应考虑进一步开发性康复计划。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验